{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:02:34Z","timestamp":1778774554019,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adding spironolactone to renin\u2010angiotensin\u2010aldosterone system (RAAS) blockers has been shown to reduce albuminuria in patients with diabetic kidney disease (DKD). However, the increased risk of hyperkalaemia is a major concern. This study aimed to evaluate the efficacy and safety of low\u2010dose (12.5\u2009mg\/day) spironolactone in reducing albuminuria and improving renal function in Iranian adults with DKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a pre\u2010post\u2010treatment study of 60 patients with type 2 diabetes, age\u2009&gt;\u200918\u2009years, albuminuria \u2265\u200930\u2009mg, estimated glomerular filtration rate (eGFR)\u2009\u2265\u200930\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>, and serum potassium level \u2264\u20095\u2009mEq\/L, who were referred to the diabetes clinic of Shariati Hospital, Tehran, Iran. The patients were prescribed spironolactone (12.5\u2009mg) once daily. Changes in urinary albumin excretion (U.Alb), urine albumin\u2010to\u2010creatinine ratio (uACR), blood pressure, serum creatinine (Cr) levels, and serum potassium levels from the baseline over the 12\u2010week intervention period were measured. Statistical significance was set at <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 12\u2009weeks of taking 12.5\u2009mg\/day spironolactone, there was a statistically significant but modest increase in eGFR (<jats:italic>p<\/jats:italic>\u2009=\u20090.042), and a statistically significant decrease was observed in both the U.Alb and uACR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There was a significant reduction in the mean Cr level (<jats:italic>p<\/jats:italic>\u2009=\u20090.003). Systolic blood pressure did not decrease significantly (<jats:italic>p<\/jats:italic>\u2009=\u20090.079), but diastolic blood pressure decreased significantly (<jats:italic>p<\/jats:italic>\u2009=\u20090.007). Changes in serum potassium levels over time were not significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.302). The reduction in albuminuria in patients taking only spironolactone and those taking spironolactone with SGLT2i was not significantly different (<jats:italic>p<\/jats:italic>\u2009=\u20090.916 and <jats:italic>p<\/jats:italic>\u2009=\u20090.948, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study found that adding spironolactone to RAAS blockers effectively reduced albuminuria, mildly increased eGFR, and improved renal outcomes in patients with DKD. Additionally, spironolactone significantly reduced albuminuria, regardless of the concurrent use of SGLT2i.<\/jats:p><\/jats:sec>","DOI":"10.1002\/edm2.70058","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T02:35:14Z","timestamp":1749177314000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Low\u2010Dose Spironolactone in Management of Diabetic Kidney Disease in a Real\u2010World Setting"],"prefix":"10.1002","volume":"8","author":[{"given":"Manochehr","family":"Amini","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Shariati Hospital, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davood","family":"Dalil","sequence":"additional","affiliation":[{"name":"School of Medicine Shahed University  Tehran Iran"},{"name":"Nephrology Research Center, Shariati Hospital Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-7111","authenticated-orcid":false,"given":"Fatemeh","family":"Yaghoubi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shariati Hospital, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoleykha","family":"Valizadeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shariati Hospital, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farnaz","family":"Tavakoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shariati Hospital, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohreh","family":"Koohpayezadeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shariati Hospital, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506634"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial2030038"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14007"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0217"},{"issue":"6","key":"e_1_2_12_7_1","first-page":"1074","article-title":"Non\u2010Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review","volume":"54","author":"Chenxi F.","year":"2023","journal-title":"Journal of Sichuan University (Medical Science Edition)"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2020.08.004"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz010"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/08860220903150312"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.508"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12629"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001854"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1106-2"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2021.1880881"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283638b1a"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000249708.44016.5c"},{"issue":"2","key":"e_1_2_12_18_1","first-page":"648","article-title":"Effects of Additive Therapy With Spironolactone on Albuminuria in Diabetes Mellitus: A Pilot Randomized Clinical Trial","volume":"4","author":"Ziaee A.","year":"2013","journal-title":"Caspian Journal of Internal Medicine"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP72449"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad144"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30026-7"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00756.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00393-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1733967"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac044"},{"key":"e_1_2_12_26_1","first-page":"1707","article-title":"A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost\u2010Effectiveness of Dapagliflozin in Three European Countries","volume":"17","author":"Khine A.","year":"2022","journal-title":"LWW"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000742021"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00240-0"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T08:37:56Z","timestamp":1753519076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/edm2.70058"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70058","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"2025-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70058"}}